MedKoo Cat#: 526793 | Name: SMND-309

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SMND-309 is a novel derivate of salvianolic acid B. SMND-309 promotes neuron survival through the activation of the PI3K/Akt/CREB-signalling pathway. SMND-309 protects rat brains ischemia and reperfusion injury by targeting the JAK2/STAT3 pathway. SMND-309 promotes angiogenesis in human umbilical vein endothelial cells through activating erythropoietin receptor/STAT3/VEGF pathways.

Chemical Structure

SMND-309
SMND-309
CAS#1065559-56-9

Theoretical Analysis

MedKoo Cat#: 526793

Name: SMND-309

CAS#: 1065559-56-9

Chemical Formula: C18H14O8

Exact Mass: 358.0689

Molecular Weight: 358.30

Elemental Analysis: C, 60.34; H, 3.94; O, 35.72

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
SMND-309; SMND 309; SMND309.
IUPAC/Chemical Name
(E)-2-[6-[(E)-2-carboxyethenyl]-2,3-dihydroxyphenyl]-3-(3,4-dihydroxyphenyl)prop-2-enoic acid
InChi Key
OAHRXWZJURTMHG-ACIWFXKJSA-N
InChi Code
InChI=1S/C18H14O8/c19-12-4-1-9(8-14(12)21)7-11(18(25)26)16-10(3-6-15(22)23)2-5-13(20)17(16)24/h1-8,19-21,24H,(H,22,23)(H,25,26)/b6-3+,11-7+
SMILES Code
O=C(O)/C(C1=C(/C=C/C(O)=O)C=CC(O)=C1O)=C/C2=CC=C(O)C(O)=C2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 358.30 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Wang Y, Zhang J, Han M, Liu B, Gao Y, Ma P, Zhang S, Zheng Q, Song X. SMND-309 promotes neuron survival through the activation of the PI3K/Akt/CREB-signalling pathway. Pharm Biol. 2016 Feb 24:1-9. [Epub ahead of print] PubMed PMID: 26911316. 2: Zhu H, Zou L, Tian J, Du G, Gao Y. SMND-309, a novel derivative of salvianolic acid B, protects rat brains ischemia and reperfusion injury by targeting the JAK2/STAT3 pathway. Eur J Pharmacol. 2013 Aug 15;714(1-3):23-31. doi: 10.1016/j.ejphar.2013.05.043. Epub 2013 Jun 11. PubMed PMID: 23764464. 3: Du G, Zhu H, Yu P, Wang H, He J, Ye L, Fu F, Zhang J, Tian J. SMND-309 promotes angiogenesis in human umbilical vein endothelial cells through activating erythropoietin receptor/STAT3/VEGF pathways. Eur J Pharmacol. 2013 Jan 30;700(1-3):173-80. doi: 10.1016/j.ejphar.2012.12.013. Epub 2012 Dec 28. PubMed PMID: 23276662. 4: Hou J, Tian J, Jiang W, Gao Y, Fu F. Therapeutic effects of SMND-309, a new metabolite of salvianolic acid B, on experimental liver fibrosis. Eur J Pharmacol. 2011 Jan 10;650(1):390-5. doi: 10.1016/j.ejphar.2010.10.019. Epub 2010 Oct 20. PubMed PMID: 20969856. 5: Yang J, Zhang G, Tian J, Li C, Jiang W, Xing Y, Zhu H, Hou J, Xu H, Wu J. Cardioprotective effect of SMND-309, a novel derivate of salvianolic acid B on acute myocardial infarction in rats. Basic Clin Pharmacol Toxicol. 2010 Apr;106(4):317-23. doi: 10.1111/j.1742-7843.2009.00490.x. Epub 2009 Nov 11. PubMed PMID: 19912162. 6: Tian J, Fu F, Li G, Gao Y, Zhang Y, Meng Q, Li C, Liu F. Protections of SMND-309, a novel derivate of salvianolic acid B, on brain mitochondria contribute to injury amelioration in cerebral ischemia rats. Phytomedicine. 2009 Aug;16(8):726-33. doi: 10.1016/j.phymed.2009.01.007. Epub 2009 May 28. PubMed PMID: 19481432. 7: Tian J, Fu F, Li G, Wang Y, Gao Y, Liu Z, Zhang S. SMND-309, a novel derivate of salvianolic acid B, ameliorates cerebral infarction in rats: characterization and role. Brain Res. 2009 Mar 31;1263:114-21. doi: 10.1016/j.brainres.2009.01.034. Epub 2009 Jan 31. PubMed PMID: 19368834. 8: Tian J, Li G, Zhang S, Gao Y, Jiang W, Fu F, Liu Z. SMND-309, a novel derivate of salvianolic acid B, attenuates apoptosis and ameliorates mitochondrial energy metabolism in rat cortical neurons. Basic Clin Pharmacol Toxicol. 2009 Feb;104(2):176-84. doi: 10.1111/j.1742-7843.2008.00349.x. Epub 2008 Dec 16. PubMed PMID: 19143749.